With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its eleventh U.S. | The FDA approved the Tecentriq label expansion alongside Natera's Signatera as a companion diagnostic.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
BeOne wins FDA approval in lymphoma race
Roche Pharma launches India’s first 7-minute injectable immunotherapy for lung cancer
Advancing Frontline Care With a Quadruplet Regimen for Transplant-Ineligible Myeloma Patients
Updated: BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
A Series A, B and an IPO; Cabaletta reports CAR-T results
AstraZeneca follows Merck with Phase 3 win in bladder cancer
Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial
Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
